| 1 |
34329582 | The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. | 2022 Feb 17 |
1 |
| 2 |
35159005 | Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. | 2022 Jan 31 |
1 |
| 3 |
31735695 | Development and Characterization of a Wee1 Kinase Degrader. | 2020 Jan 16 |
1 |
| 4 |
31200459 | Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations. | 2019 Jun 13 |
5 |
| 5 |
29954437 | Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. | 2018 Jun 28 |
4 |
| 6 |
28557434 | Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. | 2017 Jul 21 |
7 |
| 7 |
28792760 | Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. | 2017 Sep 28 |
1 |